Projects per year
Personal profile
Biography
Associate Professor Alberta Hoi is a rheumatologist, leading lupus expert and translational researcher in Australia. Her research focusses on disease predictors and outcomes, registry design and implementation, quality of care and patient-centred interactions.
She has received her undergraduate medical degree from Melbourne University (1996), and completed a doctoral of philosophy in immunology on a NHMRC scholarship from Monash University. She is a fellow of the Royal Australasian College of Physician and member of the Australian Rheumatology Association (ARA). Her current clinical activities include seeing patients at Monash Lupus Clinic, where she serves as the Clinic Head, as well as Complex Rheumatology Clinic at Monash Health, and Autoimmune Clinic at Austin Health.
She is a chief investigator and senior research fellow at the Centre for Inflammatory Diseases, School of Clinical Sciences Monash University. She has developed core set measurements and studied factors that determine optimal outcomes in SLE, and she was pivotal in the successful roll out of the Australian Lupus Registry & Biobank, a national disease registry that serves as a valuable research resource, that foster collaboration between translational scientists and clinicians at national and international levels.
Associate Professor Alberta Hoi plays an active role in a number of investigator-initiated SLE studies and clinical trials. Currently she is the chair and custodian of the Australian Lupus Registry & Biobank Steering committee. She is also on the executive committee and a founding member of the Asia-Pacific Lupus Collaboration (APLC). She serves on an honorary basis as the treasurer for the Victorian branch ARA and the Australian Chinese Medical Association Victoria.
Network
-
A Phase 2 Clinical Study to Assess the Safety and Efficacy of BMS-986165 in Participants with Active DLE and or SCLE
5/04/22 → 4/04/27
Project: Research
-
A Phase 2, Long-Term Extension (LTE) Study with Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus Who Have Completed the M19-130 Phase 2 Randomized Controlled Trial (RCT)
19/10/21 → 18/10/26
Project: Research
-
-
Cognitive dysfunction in systemic lupus erythematosus: how do we advance our understanding?
Raghunath, S., Glikmann-Johnston, Y., Hanly, J. G., Morand, E. F., Stout, J. C. & Hoi, A., 2022, (Accepted/In press) In: The Lancet Rheumatology. 10 p.Research output: Contribution to journal › Review Article › Research › peer-review
-
Purtscher-like retinopathy in anti-MDA5 dermatomyositis: a window to underlying microvasculopathy
Nohrenberg, M., Tang, Y. F., Varma, S., Fagan, X. J. & Hoi, A., 14 Jan 2022, (Accepted/In press) In: Clinical and Experimental Rheumatology. p. S1-S2 2 p.Research output: Contribution to journal › Letter › Other › peer-review
-
Advances in Translational Science to Identify New Therapies for Systemic Lupus Erythematosus
Hoi, A., Vincent, F. B. & Hibbs, M. L., 2021, Pathogenesis of Systemic Lupus Erythematosus: Insights from translational research. Hoi, A. (ed.). 1st ed. Cham Switzerland: Springer, p. 1-8 8 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Other › peer-review
-
Algorithm for calculating high disease activity in SLE
Hoi, A., Nim, H. T., Koelmeyer, R., Sun, Y., Kao, A., Gunther, O. & Morand, E., Sep 2021, In: Rheumatology. 60, 9, p. 4291-4297 7 p.Research output: Contribution to journal › Article › Research › peer-review
2 Citations (Scopus) -
Cytokines: Their Role in Amplifying SLE Pathogenesis
Liu, B. & Hoi, A., 2021, Pathogenesis of Systemic Lupus Erythematosus: Insights from Translational Research. Hoi, A. (ed.). 1st ed. Cham Switzerland: Springer, p. 109-131 23 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter (Book) › Other › peer-review